282 related articles for article (PubMed ID: 38424367)
21. Nanocarriers and Diabetes: New Vistas and the Way Ahead.
Dixit PV; Mishra DK; Sharma S; Gautam RK
Curr Pharm Biotechnol; 2023; 24(11):1420-1429. PubMed ID: 36578251
[TBL] [Abstract][Full Text] [Related]
22. Inhaled lipid nanocarriers for pulmonary delivery of glucocorticoids: Previous strategies, recent advances and key factors description.
Altube MJ; Perez N; Romero EL; Morilla MJ; Higa LH; Perez AP
Int J Pharm; 2023 Jul; 642():123146. PubMed ID: 37330156
[TBL] [Abstract][Full Text] [Related]
23. Lipid polymer hybrid nanoparticles: a custom-tailored next-generation approach for cancer therapeutics.
Gajbhiye KR; Salve R; Narwade M; Sheikh A; Kesharwani P; Gajbhiye V
Mol Cancer; 2023 Oct; 22(1):160. PubMed ID: 37784179
[TBL] [Abstract][Full Text] [Related]
24. Advances in next-generation lipid-polymer hybrid nanocarriers with emphasis on polymer-modified functional liposomes and cell-based-biomimetic nanocarriers for active ingredients and fractions from Chinese medicine delivery.
Liu Y; Xie X; Chen H; Hou X; He Y; Shen J; Shi J; Feng N
Nanomedicine; 2020 Oct; 29():102237. PubMed ID: 32534047
[TBL] [Abstract][Full Text] [Related]
25. Lipid-based drug delivery systems for cancer treatment.
Arias JL; Clares B; Morales ME; Gallardo V; Ruiz MA
Curr Drug Targets; 2011 Jul; 12(8):1151-65. PubMed ID: 21443475
[TBL] [Abstract][Full Text] [Related]
26. Targeted multifunctional lipid-based nanocarriers for image-guided drug delivery.
Koning GA; Krijger GC
Anticancer Agents Med Chem; 2007 Jul; 7(4):425-40. PubMed ID: 17630918
[TBL] [Abstract][Full Text] [Related]
27. Organ-restricted delivery through stimuli-responsive nanocarriers for lung cancer therapy.
Dinakar YH; Karole A; Parvez S; Jain V; Mudavath SL
Life Sci; 2022 Dec; 310():121133. PubMed ID: 36306866
[TBL] [Abstract][Full Text] [Related]
28. Lipid-based Nanoplatforms in Cancer Therapy: Recent Advances and Applications.
Rajpoot K
Curr Cancer Drug Targets; 2020; 20(4):271-287. PubMed ID: 31951180
[TBL] [Abstract][Full Text] [Related]
29. Lipid-based Nanocarriers for Cancer and Tumor Treatment.
Ansari MT; Ramlan TA; Jamaluddin NN; Zamri N; Salfi R; Khan A; Sami F; Majeed S; Hasnain MS
Curr Pharm Des; 2020; 26(34):4272-4276. PubMed ID: 32693760
[TBL] [Abstract][Full Text] [Related]
30. Targeted drug nanocrystals for pulmonary delivery: a potential strategy for lung cancer therapy.
Kumar M; Jha A; Dr M; Mishra B
Expert Opin Drug Deliv; 2020 Oct; 17(10):1459-1472. PubMed ID: 32684002
[TBL] [Abstract][Full Text] [Related]
31. Micelles as potential drug delivery systems for colorectal cancer treatment.
Fatfat Z; Fatfat M; Gali-Muhtasib H
World J Gastroenterol; 2022 Jul; 28(25):2867-2880. PubMed ID: 35978871
[TBL] [Abstract][Full Text] [Related]
32. Lung cancer: active therapeutic targeting and inhalational nanoproduct design.
Alhajj N; Chee CF; Wong TW; Rahman NA; Abu Kasim NH; Colombo P
Expert Opin Drug Deliv; 2018 Dec; 15(12):1223-1247. PubMed ID: 30422017
[TBL] [Abstract][Full Text] [Related]
33. Controlled drug release from lung-targeted nanocarriers via chemically mediated shell permeabilisation.
Chen H; Woods A; Forbes B; Jones S
Int J Pharm; 2016 Sep; 511(2):1033-41. PubMed ID: 27506512
[TBL] [Abstract][Full Text] [Related]
34. Active Targeting of Drugs and Bioactive Molecules via Oral Administration by Ligand-Conjugated Lipidic Nanocarriers: Recent Advances.
Shreya AB; Raut SY; Managuli RS; Udupa N; Mutalik S
AAPS PharmSciTech; 2018 Dec; 20(1):15. PubMed ID: 30564942
[TBL] [Abstract][Full Text] [Related]
35. Lipid-based Nanoparticles for the Targeted Delivery of Anticancer Drugs: A Review.
Khodaverdi H; Zeini MS; Moghaddam MM; Vazifedust S; Akbariqomi M; Tebyaniyan H
Curr Drug Deliv; 2022; 19(10):1012-1033. PubMed ID: 35078396
[TBL] [Abstract][Full Text] [Related]
36. Nano-based targeted drug delivery for lung cancer: therapeutic avenues and challenges.
Ezhilarasan D; Lakshmi T; Mallineni SK
Nanomedicine (Lond); 2022 Oct; 17(24):1855-1869. PubMed ID: 35311343
[TBL] [Abstract][Full Text] [Related]
37. Lipid-based carriers: manufacturing and applications for pulmonary route.
Jaafar-Maalej C; Elaissari A; Fessi H
Expert Opin Drug Deliv; 2012 Sep; 9(9):1111-27. PubMed ID: 22724618
[TBL] [Abstract][Full Text] [Related]
38. Inhalable particulate drug delivery systems for lung cancer therapy: Nanoparticles, microparticles, nanocomposites and nanoaggregates.
Abdelaziz HM; Gaber M; Abd-Elwakil MM; Mabrouk MT; Elgohary MM; Kamel NM; Kabary DM; Freag MS; Samaha MW; Mortada SM; Elkhodairy KA; Fang JY; Elzoghby AO
J Control Release; 2018 Jan; 269():374-392. PubMed ID: 29180168
[TBL] [Abstract][Full Text] [Related]
39. Strategy to enhance lung cancer treatment by five essential elements: inhalation delivery, nanotechnology, tumor-receptor targeting, chemo- and gene therapy.
Garbuzenko OB; Kuzmov A; Taratula O; Pine SR; Minko T
Theranostics; 2019; 9(26):8362-8376. PubMed ID: 31754402
[TBL] [Abstract][Full Text] [Related]
40. Nanotechnology-based alternatives for the topical delivery of immunosuppressive agents in psoriasis.
Gomes GS; Frank LA; Contri RV; Longhi MS; Pohlmann AR; Guterres SS
Int J Pharm; 2023 Jan; 631():122535. PubMed ID: 36566826
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
